



Sakemura RL, Manriquez Roman C, Horvei P, et al. CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS. *Blood*. 2024;143(3):258-271.

In "Acknowledgments" on page 270, financial support from the Leukemia Research Foundation to author R. Leo Sakemura should have been cited.

<https://doi.org/10.1182/blood.2024026723>

© 2024 American Society of Hematology. Published by Elsevier Inc. Licensed under [Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International \(CC BY-NC-ND 4.0\)](https://creativecommons.org/licenses/by-nc-nd/4.0/), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Downloaded from http://ashpublications.org/blood/article-pdf/144/14/1544/2244878/blood_bld-2024-026723-main.pdf by guest on 03 December 2024